Current Report Filing (8-k)
March 04 2019 - 5:29PM
Edgar (US Regulatory)
UNITED
STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 8-K
CURRENT REPORT
Pursuant to Section 13 or 15(d)
of The Securities Exchange Act of 1934
Date of Report (Date of Earliest Event Reported):
March 4, 2019
Edge Therapeutics, Inc.
(Exact name of registrant as specified in its charter)
|
|
|
Delaware
|
001-37568
|
26-4231384
|
(State or other jurisdiction
of incorporation)
|
(Commission
File Number)
|
(I.R.S. Employer
Identification No.)
|
|
|
300 Connell Drive, Suite 4000
Berkeley Heights, NJ
|
07922
|
(Address of principal executive offices)
|
(Zip Code)
|
Registrant’s telephone number, including area code
(800) 208-3343
Not Applicable
(Former name or former address, if changed since last report)
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of
the following provisions (
see
General Instruction A.2. below):
☐
|
Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
|
|
|
☐
|
Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
|
|
|
☐
|
Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
|
|
|
☐
|
Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
|
Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 or Rule 12b-2 of
the Securities Exchange Act of 1934.
Emerging growth company ☒
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with
any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.
☒
Item
7.01
|
Regulation FD Disclosure.
|
Edge Therapeutics, Inc. is furnishing the investor presentation attached as Exhibit 99.1 to this report, which it may use from time to time in
conversations with investors, analysts, and others beginning March 4, 2019.
The information in this report is being furnished pursuant to Item 7.01 and shall not be deemed to be “filed” for purposes of Section 17 of the
Securities Exchange Act of 1934, as amended (the “Exchange Act”), or otherwise subject to the liabilities of that section, nor shall it be deemed to be incorporated by reference with any filing under the Securities Act of 1933, as amended, or the
Exchange Act.
Item 9.01
|
Financial Statements and Exhibits.
|
(d) Exhibits
Exhibit
No.
|
|
Description
|
|
|
|
|
Investor Presentation, dated March 2019
|
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed
on its behalf by the undersigned hereunto duly authorized.
|
Edge Therapeutics, Inc.
|
|
|
Date: March 4, 2019
|
/s/
Andrew Saik
|
|
Name:
|
Andrew Saik
|
|
Title:
|
Chief Financial Officer
|
EDGE THERAPEUTICS, INC. (NASDAQ:EDGE)
Historical Stock Chart
From Jun 2024 to Jul 2024
EDGE THERAPEUTICS, INC. (NASDAQ:EDGE)
Historical Stock Chart
From Jul 2023 to Jul 2024